Gossamer Bio — Third Quarter 2026 Earnings Summary

Gossamer Bio submitted its first New Drug Application for seralutinib to treat pulmonary arterial hypertension to the U.S. FDA in September 2026. The company completed a 1-for-80 reverse stock split in September 2026 and reacquired worldwide rights to seralutinib from Chiesi in July 2026. A structured private placement provided $25 million in upfront capital with the potential for an additional $125 million upon FDA acceptance of the application. For the third quarter ended September 30, 2026, the company reported $51.2 million in cash, cash equivalents, and marketable securities, alongside a net loss of $48.1 million.